Lisata Therapeutics acquires Marea Therapeutics and secures $225 million
2 reports, 2 independent
Updated Sep 23
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lisata Therapeutics completed its acquisition of Marea Therapeutics on September 17, 2026. The company also entered into a private placement financing agreement expected to raise approximately $225 million gross. The acquisition was structured as a stock-for-stock transaction.
Why it matters
The acquisition allows Lisata Therapeutics to broaden its product pipeline by integrating Marea Therapeutics' focus on cardioendocrine diseases. The expected funding is projected to support Lisata Therapeutics' operations through 2028, aligning with planned clinical milestones.